Unique medical breakthroughs in the world of cancer

New independent study found that Zometa (Zoledronic Acid) when added to hormone therapy, following surgery, significantly reduced the risk of cancer recurrence or death by 36%, beyond clinical benefits achieved with hormone therapy alone in premenopausal women with early-stage breast cancer.

This was announced at the Annual American Society of Clinical Oncology (ASCO) meeting held in Chicago last month.

The most important conference to deliver new scientific researches in the field of cancer worldwide.

On this note, Prof. Joseph Kattan held a press conference in Beirut, Lebanon to discuss the impact of this finding on cancer patients in the Arab region.

He explained that in Lebanon, there is more than 50% increase in breast Cancer cases in young women.

"The research we are unraveling today has proven that Zometa can serve to re-shape the way we treat cancer around the world".

The independent study was led by Dr. Michael Gnant, M.D., of the Medical University of Vienna.

The research enrolled 1,803 premenopausal women taking hormone therapy for early-stage breast cancer.

It was found that Zometa when added to hormone therapy cut by one-third the chances of cancer reoccurrence or death beyond clinical benefits achieved with hormone therapy alone.

"These important findings may well change the standard of medical practice of premenopausal women with hormone-sensitive breast cancer" Said Prof. Joseph Kattan.

"Only 30-40% of cancer patients are cured, mainly when we discover the disease in a late stage, therefore the result of this research is a revolt that expectantly will change the concept of treatment in the world of cancer, and change the horizon for many many patients." said Prof. Kattan.